Lucis, a Paris-based preventive health platform that uses blood biomarker analysis and AI to deliver personalised, science-based health recommendations, has raised €17.1 million ($20 million) in Series A funding.
The round was led by Singular, with participation from General Catalyst, Y Combinator, and angels including investors behind Runna, Céline Lazorthes (Resilience), and Manu Lecomte. This round follows Lucis’s €7.2 million ($8.5 million) Seed round raised in December 2025, bringing total funding to €24 million ($28 million).
Maxime Berthelot, co-founder and CEO, Lucis, said, “We’ve seen the devastating impact of late-stage diagnosis first-hand. The science is already there; what’s missing is a system designed to act before symptoms appear. This is why we built Lucis. By combining biomarker data and AI-driven clinical insights, we can catch what the system misses. Europe deserves a healthcare model that doesn’t wait for people to get sick. We are making prevention the default, rather than a privilege.”
Founded in 2025 by Maxime Berthelot and Baptiste Debever, Lucis claims to provide individuals with a comprehensive, data-driven view of their health. The platform analyses more than 110 blood biomarkers across key systems, including metabolic health, hormones, cardiovascular risk, inflammation, and nutrient levels.
The company states that these results are integrated into an AI-driven health companion app, which uses longitudinal data and medical context to provide personalised advice on nutrition, supplements, lifestyle adjustments, and follow-up testing.
It points out that the recommendations are continuously refined as new data becomes available and are reviewed by physicians, helping users understand what actions to take, not just what the data shows.
Lucis reports that early data from its growing user base of over 10,000 indicate meaningful health outcomes and sustained engagement. Among users who completed a six-month follow-up, 75% improved at least three biomarkers without medication. It also noted that more than 80% opted to retest, suggesting continued engagement with the platform and their health data.
During initial testing, 99.9% of users had at least one biomarker outside the optimal range, often without knowing it beforehand. This underscores how potential health risks can easily go unnoticed without regular monitoring, says the company.
Since its launch in 2025, Lucis has expanded to over 10,000 users in France, the UK, Ireland, and Portugal, and has conducted more than one million biomarker tests. Additionally, the company has developed a community of thousands of members and formed partnerships with laboratory groups such as Eurofins and Randox.
Today, Lucis has a team of 20 across engineering, clinical, growth, and operations, along with a medical board and an expanding network of over 10 physicians providing clinical oversight.
Jeremy Uzan, co-founder and GP at Singular, said, “Europe’s preventive health category will be won by platforms that unite clinical credibility with AI at scale. Lucis has moved with remarkable velocity, reaching 10,000 users in under a year, delivering measurable outcomes and building a compounding data advantage that sets the standard for the category. We see Lucis as a clear category winner in Europe and are excited to partner with the team as the product continues to evolve alongside customer needs.”
With the fresh funding, the company aims to support expansion across Europe and continued development of its AI-driven health companion app. It plans to expand into Spain, Germany, and Italy by the end of 2026, while continuing to invest in personalisation, longitudinal monitoring, and clinical safety.
Read the orginal article: https://www.eu-startups.com/2026/05/yc-backed-french-preventive-health-platform-lucis-raises-e17-3-million-series-a-led-by-singular/
